FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W92937101> ?p ?o ?g. }

• W92937101 endingPage "986" @default.
• W92937101 startingPage "977" @default.
• W92937101 abstract "Provision of adequate T cell costimulation is critical for the development of acute and chronic allograft rejection. We have previously reported that early blockade of CD28-B7 T cell costimulation prevents the development of graft arteriosclerosis, in the LEW into F344 rat cardiac transplant model. In this study, we used the same model to examine the requirement for CD28-B7-mediated T cell costimulation in the progression of established chronic rejection and examined the individual roles of B7–1 (CD80) and B7–2 (CD86) costimulatory molecules. Late blockade of CD28-B7 T cell costimulation by the fusion protein CTLA4Ig, which binds both CD80 and CD86, attenuated the development of transplant arteriosclerosis, mononuclear cell infiltration, and parenchymal fibrosis in this model. Selective blockade of CD80 using the mutant fusion protein Y100F was as effective as CTLA4Ig in this regard. In contrast to CTLA4Ig, blockade of CD80 alone by Y100F was ineffective at preventing early graft loss and prolonging graft survival when given early after transplantation. This study is the first to demonstrate that late blockade of CD28-B7 T cell costimulation interrupts chronic cardiac allograft rejection, and it indicates the importance of continued T cell activation in this process. This study further defines functional differences between CD80 and CD86 costimulatory molecules in vivo. Provision of adequate T cell costimulation is critical for the development of acute and chronic allograft rejection. We have previously reported that early blockade of CD28-B7 T cell costimulation prevents the development of graft arteriosclerosis, in the LEW into F344 rat cardiac transplant model. In this study, we used the same model to examine the requirement for CD28-B7-mediated T cell costimulation in the progression of established chronic rejection and examined the individual roles of B7–1 (CD80) and B7–2 (CD86) costimulatory molecules. Late blockade of CD28-B7 T cell costimulation by the fusion protein CTLA4Ig, which binds both CD80 and CD86, attenuated the development of transplant arteriosclerosis, mononuclear cell infiltration, and parenchymal fibrosis in this model. Selective blockade of CD80 using the mutant fusion protein Y100F was as effective as CTLA4Ig in this regard. In contrast to CTLA4Ig, blockade of CD80 alone by Y100F was ineffective at preventing early graft loss and prolonging graft survival when given early after transplantation. This study is the first to demonstrate that late blockade of CD28-B7 T cell costimulation interrupts chronic cardiac allograft rejection, and it indicates the importance of continued T cell activation in this process. This study further defines functional differences between CD80 and CD86 costimulatory molecules in vivo. Chronic rejection is the major cause of late graft loss in solid organ transplantation.1Weis M von-Scheidt W Cardiac allograft vasculopathy: a review.Circulation. 1997; 96: 2069-2077Crossref PubMed Scopus (401) Google Scholar It is characterized histologically by the development of transplant arteriosclerosis, a vasculopathy consisting of concentric fibrointimal thickening in large and medium-sized arteries and arterioles.2Russell ME Hancock WW Akalin E Wallace AF Glysing-Jensen T Willett TA Sayegh MH Chronic cardiac rejection in the LEW to F344 rat model.J Clin Invest. 1995; 97: 833-838Crossref Scopus (161) Google Scholar Other cardinal histological features of chronic rejection include perivascular and interstitial mononuclear cell infiltrates and parenchymal fibrosis. The etiology of chronic rejection remains undefined, but increasing evidence suggests that it may represent a common immune-mediated injury response to multiple etiological factors. This is exemplified by the many disparate risk factors that predispose to its development, including alloantigen-dependent factors such as major histocompatibility complex (MHC) incompatibility and alloantigen-independent factors such as perioperative ischemic graft damage, viral infections, and hyperlipidemia.3Tullius S Tilney N Both alloantigen-dependent and -independent factors influence chronic allograft rejection.Transplantation. 1995; 59: 313-318Crossref PubMed Scopus (381) Google ScholarWe are currently investigating the role of the CD4+ T cell in the initiation and coordination of the immune response underlying chronic rejection. T lymphocytes require two signals to become fully activated: an antigen-dependent signal induced by ligation of the T cell receptor and a costimulatory signal induced predominantly by ligation of T cell CD28 with a member of the B7 family of molecules (CD80 or CD86) on antigen-presenting cells.4Janeway C Bottomly K Signals and signs for lymphocyte responses.Cell. 1994; 76: 275-285Abstract Full Text PDF PubMed Scopus (766) Google Scholar Ligation of CD28 is necessary for maximal CD4+ T cell cytokine production, proliferation and prevention of activation-induced apoptosis. CD80 and CD86 are the only ligands for T cell CD28 and interactions between both ligands and CD28 are interrupted by CTLA4Ig,5Linsley PS Brady W Urnes M Grosmaire LS Damle NK Ledbetter JA CTLA-4 is a second receptor for the B cell activation antigen B7.J Exp Med. 1991; 174: 561-569Crossref PubMed Scopus (1518) Google Scholar a recombinant fusion protein that contains the extracellular domain of human CTLA4, a homologue of CD28, fused to a human IgG1 heavy chain. Blockade of CD28-B7 interactions using CTLA4Ig prevents CD4+ T cell activation in response to alloantigen and leads to antigen-specific T cell anergy.6Gimmi C Freeman G Gribben J Gray G Nadler L Human T cell anergy is induced by antigen presentation in the absence of B7 costimulation.Proc Natl Acad Sci USA. 1993; 90: 6586-6590Crossref PubMed Scopus (548) Google Scholar CTLA4Ig is effective in preventing allograft rejection and inducing transplantation tolerance in several experimental transplant models.7Lenschow DJ Zeng Y Thistlethwaite JR Montag A Brady W Gibson MG Linsley PS Bluestone JA Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg.Science. 1992; 257: 789-792Crossref PubMed Scopus (1097) Google Scholar Thus, costimulatory blockade using CTLA4Ig provides an experimental tool to examine the role of T cell activation in the initiation and progression of chronic allograft rejection.We have previously shown that inhibition of T cell activation early after transplantation by blocking T cell costimulation with CTLA4Ig results in long term survival in the majority of grafts and prevents the development of graft arteriosclerosis in the LEW to F344 rat heterotopic cardiac transplant model.2Russell ME Hancock WW Akalin E Wallace AF Glysing-Jensen T Willett TA Sayegh MH Chronic cardiac rejection in the LEW to F344 rat model.J Clin Invest. 1995; 97: 833-838Crossref Scopus (161) Google Scholar, 8Adams D Russell M Hancock W Sayegh M Wyner L Karnovsky M Chronic rejection in experimental cardiac transplantation: studies in the Lewis-F344 model.Immunol Rev. 1993; 134: 5-19Crossref PubMed Scopus (71) Google Scholar In these studies, we wished to determine the role of continued T cell activation on the progression of chronic rejection in this model by examining the effects of late T cell costimulation blockade. Furthermore, we used the mutant form of CTLA4Ig, Y100F, to determine the effects of selective CD80 blockade at early and late time points post-transplant in the development of chronic rejection.Materials and MethodsAnimals, Reagents, and Experimental ProtocolsInbred adult male LEW and F344 rats were purchased from Harlan Sprague-Dawley (Indianapolis, IN). F344 rats served as recipients of LEW cardiac allografts. Hearts were transplanted to the infrarenal great vessels by standard microvascular techniques as described previously2Russell ME Hancock WW Akalin E Wallace AF Glysing-Jensen T Willett TA Sayegh MH Chronic cardiac rejection in the LEW to F344 rat model.J Clin Invest. 1995; 97: 833-838Crossref Scopus (161) Google Scholar, 9Sayegh M Sablinski T Tanaka K Kut J Kwok C Tilney N Kupiec-Weglinski J Milford E Effects of BWH-4 anti-CD4 monoclonal antibody on rat vascularized cardiac allografts before and after engraftment.Transplantation. 1991; 51: 296-299Crossref PubMed Scopus (33) Google Scholar under ether anesthesia. F344-to-F344 and LEW-to-LEW isografts served as controls. Graft function was monitored by daily palpation of the transplanted heart; time of rejection was defined as the day of complete cessation of myocardial contraction. Allografts were harvested routinely at day 120 or after rejection. Survival estimates were calculated using the Kaplan Meier test and the log rank test was used to compare differences in survival between groups. CTLA4Ig, mutant CTLA4Ig Y100F and control fusion protein L6 (Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ)10Chandraker A Takada M Nadeau K Peach R Tilney N Sayegh M CD28–B7 blockade in organ dysfunction secondary to cold ischemia-reperfusion injury.Kidney Int. 1997; 52: 1678-1684Crossref PubMed Scopus (91) Google Scholar were used to study the role of CD28-B7 T cell costimulatory molecule blockade on the course of chronic rejection. Y100F is a mutant form of CTLA4Ig that selectively binds CD80. Figure 1 shows the dose and time course of treatment in each group.Morphometric and Histological AnalysesCoronal sections of graft tissue were fixed in 10% formaldehyde, embedded in paraffin, sectioned, and stained with Verhoeff’s elastin (arteriosclerosis scoring) or Masson’s trichrome (fibrosis and infiltrate scoring). Arteriosclerosis was assessed by light microscopy and percentage luminal occlusion by intimal thickening determined using the scoring system (scale, 0–5) described by Adams et al.11Adams D Tilney N Collins J Karnovsky M Experimental graft arteriosclerosis I. The Lewis to F-344 allograft model.Transplantation. 1992; 53: 1115-1119Crossref PubMed Scopus (130) Google Scholar All arteries seen were examined and scored by two blinded examiners. A total of 325 vessels were analyzed with an average of 14 scored per graft. Only vessels that were cut orthogonally and displayed a clear internal elastic lamina were scored.Matched trichrome-stained sections were also scored by a pathologist (RM) blinded for the treatment groups to look for fibrosis, interstitial cellular infiltration, and vasculitis. Each of these categories was graded, and the average grade was calculated for each group. Fibrosis was quantified by collagen deposition highlighted by trichrome stain and scored on a 0–3 scale where 0 indicated no fibrosis, and 1, 2, and 3 indicated mild, moderate, and severe fibrosis, respectively. A scale of 0–4 was used for scoring the degree of interstitial mononuclear cell infiltration, where 0 indicated no cellular infiltration and 1, 2, 3, and 4 indicated minimal, mild, moderate, and severe cellular infiltration, respectively. Vasculitis was assessed by the degree of inflammatory cell adhesion to the endothelial surface and infiltration of the muscle layer, which was scored 0 (up to 10% of all vessels were involved), 1 (10–50%), or 2 (>50%).Nonparametric statistical tests were used to compare arteriosclerosis scores and fibrosis scores. The Kruskal-Wallis analysis of variance test was used to assess variance between groups and Dunn’s Post test was then used to determine differences between individual groups.Isolation of RNA and Reverse Transcription Polymerase Chain Reaction (PCR) AnalysisTotal RNA was extracted from frozen tissue specimens using the Ultraspec RNA isolation system (Biotecx, Houston, TX) and was quantified by spectrophotometry. cDNA was prepared by reverse transcription of 5 μg of RNA using random hexamer primers (100 ng/μl) and Moloney murine leukemia virus reverse transcriptase (50 u/μl) (Stratagene, La Jolla, CA) in a 50-μl reaction. Ten microliters of cDNA were used for each PCR amplification reaction. PCR was performed with Taq DNA polymerase using the buffer supplied by the manufacturer (Boehringer Mannheim, Indianapolis, IN). Primers and PCR conditions used were, for monocyte chemotactic peptide-1(MCP-1): 5′-ATGCAGGTCTCTGTCACG-3′ and 3′-CTAGTTCTCTGTCATACT-5′ (50°C, 28 cycles); for inducible nitric oxide synthase: 5′-TGCCAGGGTCACAACTTTACAGG-3′ and 3′-GGTCGATGTCACATGCAGCTTGTC-5′ (60°C, 35 cycles); and for transforming growth factor-β (TGF-β) 5′-TGAACCAAGGAGACGGAATACAGG-3′ and 3′-TACTGTGTGTCCAGGCTCCAAATG-5′ (57°C, 26 cycles; Integrated DNA Technologies, Coralville, IA). The PCR conditions were 94°C for 30 seconds, 50–60°C for 30 seconds, and 72°C for 2 minutes. PCR products were analyzed by ethidium bromide staining in 1.5% agarose gels using standard techniques. The densitometric band densities were measured using computerized imaging software (ALpha-Imager, version 0.1.12, Alpha Innotech Corp, San Leandro, CA). Glyceraldehyde-3-phosphate dehydrogenase gene products were simultaneously measured and used to correct for variations in cDNA amounts between samples.2Russell ME Hancock WW Akalin E Wallace AF Glysing-Jensen T Willett TA Sayegh MH Chronic cardiac rejection in the LEW to F344 rat model.J Clin Invest. 1995; 97: 833-838Crossref Scopus (161) Google Scholar, 12Knoflach A Azuma H Magee C Denton M Murphy B Iyenger A Buelow R Sayegh M Immunomodulatory functions of low-molecular weight hyaluronate in an acute rat renal allograft rejection model.J Am Soc Nephrol. 1999; 10: 1059-1066Crossref PubMed Google ScholarRat Carotid Balloon Injury ModelTwenty male Sprague-Dawley rats (275–300 g) underwent endothelial denudation of the left carotid artery (Zivic Miller, Zelienople, PA).13Hancock W Adams D Wyner L Sayegh M Karnovsky M CD4+ mononuclear cells induce cytokine expression, vascular smooth muscle cell proliferation and arterial occlussion after endothelial injury.Am J Pathol. 1994; 145: 1008-1014PubMed Google Scholar Rats were randomized to daily i.p. injections of 1 mg CTLA4Ig (Bristol-Myers Squibb, Seattle, WA) diluted in phosphate-buffered saline (1 mg/ml) or vehicle control for 14 days, beginning on the day of injury. On day 14, the left (injured) and right (uninjured) carotids were dissected and removed. The center piece of the carotid artery was fixed in methyl carnoys and embedded in paraffin. Four-micron sections were treated with Verhoeff’s stain to identify the elastic lamina.14Russel M Hancock W Akalin E Wallace A Glysing-Jensoen T Willet T Sayegh M Chronic cardiac rejection in the Lewis to F344 rat model: blockade of CD28–B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis.J Clin Invest. 1995; 97: 833-838Crossref Google Scholar Using Scion Image 1.55, morphometric analysis was completed on elastin-stained sections by measuring the area of the lumen (L), internal elastic lamina (IEL), and external elastic lamina (EEL). These measurements were then used to determine the percentage of luminal occlusion, (IEL-L/IEL) × 100, and intima-to-media ratio, IEL/(EEL-IEL). The measurements were tabulated for three separate sections per carotid. Mean scores were pooled for the two subgroups and are reported as the mean levels ± SD. Results were subjected to analysis of variance to evaluate significant differences between CTLA4Ig and control groups.ResultsLate Blockade of CD4+ T Cell Costimulation with CTLA4Ig Interrupts the Development of Chronic RejectionWe have previously shown that a single injection of CTLA4Ig on day 2 post-transplantation prevented development of graft arteriosclerosis in the LEW into F344 model of chronic cardiac allograft rejection.2Russell ME Hancock WW Akalin E Wallace AF Glysing-Jensen T Willett TA Sayegh MH Chronic cardiac rejection in the LEW to F344 rat model.J Clin Invest. 1995; 97: 833-838Crossref Scopus (161) Google Scholar We now report the effects of late CD28-B7 blockade by administration of CTLA4Ig starting on day 30 or 60 post-transplantation. This is a clinically relevant strategy, because it addresses the issue of interruption of progression of chronic rejection and the therapy of established disease. Illustrated in Figure 2 is the percentage of survival of allografts within each experimental group plotted against time. Whereas approximately 50% of grafts from the control group 3 rejected before 120 days, all isografts and the majority of grafts from CTLA4Ig-treated animals (groups 1 and 2) survived to >120 days (time of harvest;P < 0.05 by Kaplan Meier). Thus, blocking T cell costimulation by CTLA4Ig late after acute graft injury was effective in preventing chronic graft loss.Figure 2Kaplan-Meier survival plot for cardiac allografts from groups 1 to 4. Allografts surviving to 120 days were routinely harvested. Survival for each group was graphed together for the first 30 days post-transplant, after which time treatment regimes diverged. There was no loss of any of the transplants post-day 30 in the isograft (group 4) or CTLA4 Ig-treated groups (groups 1 and 2). This was significantly different from the control L6-treated (group 3) in which 50% of the allografts surviving to day 30 had stopped by day 120 (P < 0.05 by Kaplan-Meier), giving an overall survival of 45%.View Large Image Figure ViewerDownload Hi-res image Download (PPT)Grafts surviving >100 days were examined histologically for graft arteriosclerosis. Shown in Table 1 are the mean arteriosclerosis scores for each group. Control animals (group 3) develop significant arteriosclerosis (mean intimal thickening score was 1.68 ± 0.81 with 55.93 ± 26.06% of the total number of vessels found to be diseased). In comparison, isografts do not develop arteriosclerosis (mean intimal thickening score for isografts was 0.14 ± 0.14 with 2.78 ± 4.81% of vessels diseased;P < 0.001). Late blockade of T cell costimulation with CTLA4Ig starting on day 30 or day 60 is associated with a significant attenuation of graft arteriosclerosis as compared to controls (P < 0.001). Interestingly, more prolonged costimulatory blockade (90 days in group 1 vs. 60 days in group 2) was associated with greater attenuation of graft arteriosclerosis. Representative vessels from isografts and allografts from control and CTLA4Ig-treated groups are shown in Figure 3.Table 1CTLA4Ig Interrupts Progression of Transplant ArteriosclerosisGroupnVessel scoreDiseased vessel (%)CTLA4Ig 30–12060.39 ± 0.30*P < 0.001 using an analysis of variance with Bonferroni correction.16.32 ± 13.21*P < 0.001 using an analysis of variance with Bonferroni correction.CTLA4Ig 60–12050.57 ± 0.35*P < 0.001 using an analysis of variance with Bonferroni correction.25.35 ± 12.76*P < 0.001 using an analysis of variance with Bonferroni correction.Control Ig61.68 ± 0.8155.93 ± 26.06Isograft70.14 ± 0.14*P < 0.001 using an analysis of variance with Bonferroni correction.2.78 ± 4.81*P < 0.001 using an analysis of variance with Bonferroni correction.Comparison of group versus control Ig-treated group. Values expressed as means ± SD.* P < 0.001 using an analysis of variance with Bonferroni correction. Open table in a new tab Figure 3Representative paraffin sections of rat cardiac transplants at 120 days post-transplant demonstrating transplant arteriosclerosis (Van Gieson stain) from (A) isografts (group 4), (B) control L6-treated (group 3), (C) 90 day CTLA4Ig-treated animals (group 1), and (D) 60 day CTLA4Ig-treated animals (group 2).View Large Image Figure ViewerDownload Hi-res image Download (PPT)Grafts surviving >100 days were examined histologically for parenchymal fibrosis, leukocyte infiltration, and vasculitis, and severity scores were determined blindly by an experienced pathologist. Scores for each treatment group are shown in Table 2. The amount of fibrosis was significantly greater in allografts from control group 3 as compared to isografts (group 4) and allografts from animals treated with CTLA4Ig from day 30 (Group 1; P < 0.05). Although allografts from animals treated with CTLA4Ig from day 60 (group 2) had an intermediate degree of fibrosis; this did not reach statistical difference when compared with control L6-treated animals (group 3). Similar results were also obtained when the amount of cellular infiltration within allografts was compared. Grafts from control L6-treated animals (group 3) demonstrated marked cellular infiltration, which was significantly less in grafts from animals treated with CTLA4Ig from day 30 (group 1; P < 0.05). Consistent with previous findings using this model, acute vasculitic changes were minimal in all groups. Representative histology showing fibrosis and inflammatory infiltration are shown in Figure 4.Table 2Effect of T Cell Costimulatory Blockade on Fibrosis, Interstitial Infiltration, and VasculitisGroupnFibrosisInflammationVasculitisCTLA4Ig 30–12060.33 ± 0.21*P < 0.001 using an analysis of variance with Bonferroni correction.0*P < 0.001 using an analysis of variance with Bonferroni correction.0.33 ± 0.33CTLA4Ig 60–12051.6 ± 0.511.6 ± 0.680.6 ± 0.25Control Ig62.17 ± 0.173.0 ± 0.370.83 ± 0.4Isograft70.29 ± 0.18*P < 0.001 using an analysis of variance with Bonferroni correction.0.14 ± 0.14*P < 0.001 using an analysis of variance with Bonferroni correction.0.29 ± 0.29Comparison of group versus control Ig-treated group. Values expressed as means ± SD.* P < 0.001 using an analysis of variance with Bonferroni correction. Open table in a new tab Figure 4Representative paraffin sections of rat cardiac transplants at 120 days post-transplant demonstrating graft fibrosis (Trichrome stain) from (A) control L6 treated (group 3), (B) isografts (group 4), (C) 60 day CTLA4Ig animals (group 2), and (D) 90 day CTLA4Ig treated animals (group 1) and interstitial inflammatory infiltrate (E) control L6-treated (group 3), (F) isografts (group 4), (G) 60 day CTLA4Ig-treated animals (group 2), and (H) 90 day CTLA4Ig-treated animals (group 1).View Large Image Figure ViewerDownload Hi-res image Download (PPT)Effects of Early and Late Selective Blockade of CD80 on the Development of Chronic RejectionEvidence suggests that CD80 and CD86 may have functionally distinct roles in T cell activation. In general, CD86 is constitutively expressed and rapidly up-regulated on antigen-presenting cells, whereas CD80 is not usually expressed until after prolonged (72 hours) stimulation. These differences may suggest that CD86 is important in mediating initial T cell alloactivation and CD80 is important in perpetuation of the immune response, although this has not been established in an experimental transplant model.To examine the effects of interrupting CD80-mediated T cell costimulation at early and late time points post-transplantation in this model, we used the mutant CTLA4Ig Y100F, an agent that selectively binds CD80. Administration of Y100F (0.5 mg i.p.) as a single dose on day 2 or as repeated twice-weekly doses post-transplantation did not prolong graft survival (Figure 5A). This is in striking contrast to the effects of CTLA4Ig (0.5 mg i.p.) given on day 2, which resulted in prolonged graft survival (>100 days) in over 60% of recipients.14Russel M Hancock W Akalin E Wallace A Glysing-Jensoen T Willet T Sayegh M Chronic cardiac rejection in the Lewis to F344 rat model: blockade of CD28–B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis.J Clin Invest. 1995; 97: 833-838Crossref Google Scholar We next examined whether late administration of Y100F was effective in attenuating chronic rejection in this model. In these experiments we compared Y100F to CTLA4Ig in a modified “interruption” treatment protocol consisting of twice-weekly injections of Y100F from day 30 to day 60. In contrast to the lack of efficacy of Y100F early post-transplantation, we find that Y100F is as effective as CTLA4Ig when given late post-transplantation in interrupting chronic rejection. Illustrated in Figure 5B is the percentage survival of allografts in Y100F-treated (group 8), CTLA4Ig-treated (group 9), and control L6-treated groups (group 10). Both Y100F and CTLA4Ig result in a significant prolongation of allograft survival (P < 0.05).Figure 5Kaplan Meier survival plots showing effects of administration of Y100F early (A) and late (B) post-transplantation. Number of animals in each group is shown in parentheses.View Large Image Figure ViewerDownload Hi-res image Download (PPT)When grafts surviving >100 days were examined for arteriosclerosis, grafts from Y100F-treated animals had significantly less arteriosclerosis than controls (P < 0.001) (Figure 6A). There was a trend toward less arteriosclerosis in grafts from Y100F- compared to CTLA4Ig-treated groups. Representative vessels from allografts from control and Y100F- and CTLA4Ig-treated groups are shown in Figure 7. Furthermore, late blockade of CD80/CD28 interactions with Y100F is associated with reduced parenchymal fibrosis (Figure 6B) and inflammatory cell infiltration (data not shown) compared to controls. In keeping with these observations we find lower levels of mRNA expression of the chemotactic agent MCP-1 and the fibrogenic cytokine TGF-β in grafts from Y100F treated recipients compared to controls (Figure 6C). We also find lower levels of expression of the Th-1 cytokine interferon-γ in grafts from Y100F animals. This may reflect either a deviation from Th1 differentiation with CD80 blockade or simply a reduction in immune cell infiltration.Figure 6A: Arteriosclerosis scores in treatment groups. Mean number of vessels counted per graft was 9.1. Shown are mean arteriosclerosis scores for each animal and mean for each group. Percentage of diseased vessels for each group were (i) Y100F-treated (group 8): 57 ± 19%; (ii) CTLA4Ig-treated (group 9): 72 ± 22%; and (iii) L6-treated (group 10) 87 ± 16%. B: Mean graft fibrosis score for each group as calculated by experienced pathologist. C: Levels of expression of graft mRNA for MCP-1, interferon-γ, and TGF-β in Y100F- and control L6-treated groups. Levels are expressed in arbitrary units of fluorescence intensity obtained by optical imaging.View Large Image Figure ViewerDownload Hi-res image Download (PPT)Figure 7Representative paraffin sections demonstrating graft arteriosclerosis (Van Gieson stain) in rat cardiac transplants surviving >100 days post-transplant from (A) L6-treated controls (group 10), (B) CTLA4Ig-treated animals (group 9), and (C) Y100F-treated animals (group 8).View Large Image Figure ViewerDownload Hi-res image Download (PPT)To investigate whether the observed effect of CTLA4Ig or Y100F is due merely to increased immunosuppression versus a specific effect of T cell costimulatory activation blockade, we examined the effects of continuous immunosuppression with low-dose CsA in this model. Whereas continuous CsA treatment prolonged graft survival, we found that mean transplant arteriosclerosis scores were no different from controls (1.73 ± 1.53; P = n.s.). Furthermore, grafts exhibited marked parenchymal fibrosis, consistent with the ability of CsA to induce expression of the potent fibrogenic growth factor TGF-β15Prashar Y Khanna A Sehajpal P Sharma V Suthanthiran M Stimulation of transforming growth factor-beta 1 transcription by cyclosporine.FEBS Lett. 1995; 358: 109-112Abstract Full Text PDF PubMed Scopus (96) Google Scholar (data not shown).Effect of Blocking T Cell Costimulation on the Development of Intimal Proliferation in a Rat Carotid Balloon Injury ModelWe next wished to confirm that the effects of CTLA4Ig were a direct consequence of prevention of T cell costimulation/activation rather than a nonspecific anti-inflammatory effect or an effect on monocytes/macrophages or endothelial cell activation that is independent of T cell activation. To address this issue, we studied the effect of CTLA4Ig on the development of arteriosclerosis in a vascular endothelial injury model where activated T lymphocytes do not play a role in the pathogenesis of lesion formation. In this model, rat carotid arteries undergo endothelial injury by balloon angioplasty. The animals develop arteriosclerosis secondary to endothelial and monocyte/macrophage activation. Carotid arteries from CTLA4Ig and control saline-treated animals were analyzed histologically and percentage of luminal occlusion determined as described above in Methods.13Hancock W Adams D Wyner L Sayegh M Karnovsky M CD4+ mononuclear cells induce cytokine expression, vascular smooth muscle cell proliferation and arterial occlussion after endothelial injury.Am J Pathol. 1994; 145: 1008-1014PubMed Google Scholar Mean percent luminal occlusion was 56 ± 12% in CTLA4Ig-treated rats compared to 49 ± 25% in saline-treated rats (P = 0.44). Intima-to-media ratios were also similar: 1.2 ± 0.3 in CTLA4Ig-treated rats compared with 0.9 ± 0.4 in saline-treated group (P = n.s.). Thus, blockade of T cell costimulation did not inh" @default.
• W92937101 created "2016-06-24" @default.
• W92937101 creator A5005922624 @default.
• W92937101 creator A5028211848 @default.
• W92937101 creator A5035019435 @default.
• W92937101 creator A5036437333 @default.
• W92937101 creator A5045569677 @default.
• W92937101 creator A5046964205 @default.
• W92937101 creator A5054858357 @default.
• W92937101 creator A5058866981 @default.
• W92937101 creator A5067871845 @default.
• W92937101 creator A5071460212 @default.
• W92937101 date "2001-03-01" @default.
• W92937101 modified "2023-10-17" @default.
• W92937101 title "CD28-B7-Mediated T Cell Costimulation in Chronic Cardiac Allograft Rejection" @default.
• W92937101 cites W1490311916 @default.
• W92937101 cites W1620848284 @default.
• W92937101 cites W1973281835 @default.
• W92937101 cites W1989914829 @default.
• W92937101 cites W1995980770 @default.
• W92937101 cites W1998121841 @default.
• W92937101 cites W2001868699 @default.
• W92937101 cites W2009326258 @default.
• W92937101 cites W2022745297 @default.
• W92937101 cites W2025123869 @default.
• W92937101 cites W2035455050 @default.
• W92937101 cites W2035881418 @default.
• W92937101 cites W2038879559 @default.
• W92937101 cites W2040838085 @default.
• W92937101 cites W2053620210 @default.
• W92937101 cites W2059165131 @default.
• W92937101 cites W2061284405 @default.
• W92937101 cites W2071246977 @default.
• W92937101 cites W2077389439 @default.
• W92937101 cites W2077627479 @default.
• W92937101 cites W2078843264 @default.
• W92937101 cites W2087013294 @default.
• W92937101 cites W2087757222 @default.
• W92937101 cites W2103806658 @default.
• W92937101 cites W2152443558 @default.
• W92937101 cites W2164903177 @default.
• W92937101 cites W2172960056 @default.
• W92937101 cites W2412367076 @default.
• W92937101 cites W2413206212 @default.
• W92937101 cites W4250399467 @default.
• W92937101 cites W93919072 @default.
• W92937101 doi "https://doi.org/10.1016/s0002-9440(10)64044-8" @default.
• W92937101 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1850369" @default.
• W92937101 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11238045" @default.
• W92937101 hasPublicationYear "2001" @default.
• W92937101 type Work @default.
• W92937101 sameAs 92937101 @default.
• W92937101 citedByCount "63" @default.
• W92937101 countsByYear W929371012012 @default.
• W92937101 countsByYear W929371012013 @default.
• W92937101 countsByYear W929371012014 @default.
• W92937101 countsByYear W929371012015 @default.
• W92937101 countsByYear W929371012017 @default.
• W92937101 countsByYear W929371012018 @default.
• W92937101 countsByYear W929371012019 @default.
• W92937101 countsByYear W929371012021 @default.
• W92937101 crossrefType "journal-article" @default.
• W92937101 hasAuthorship W92937101A5005922624 @default.
• W92937101 hasAuthorship W92937101A5028211848 @default.
• W92937101 hasAuthorship W92937101A5035019435 @default.
• W92937101 hasAuthorship W92937101A5036437333 @default.
• W92937101 hasAuthorship W92937101A5045569677 @default.
• W92937101 hasAuthorship W92937101A5046964205 @default.
• W92937101 hasAuthorship W92937101A5054858357 @default.
• W92937101 hasAuthorship W92937101A5058866981 @default.
• W92937101 hasAuthorship W92937101A5067871845 @default.
• W92937101 hasAuthorship W92937101A5071460212 @default.
• W92937101 hasBestOaLocation W929371011 @default.
• W92937101 hasConcept C126322002 @default.
• W92937101 hasConcept C142724271 @default.
• W92937101 hasConcept C148125776 @default.
• W92937101 hasConcept C203014093 @default.
• W92937101 hasConcept C2776090121 @default.
• W92937101 hasConcept C2778849806 @default.
• W92937101 hasConcept C2911091166 @default.
• W92937101 hasConcept C3019230761 @default.
• W92937101 hasConcept C71924100 @default.
• W92937101 hasConcept C86803240 @default.
• W92937101 hasConcept C8891405 @default.
• W92937101 hasConceptScore W92937101C126322002 @default.
• W92937101 hasConceptScore W92937101C142724271 @default.
• W92937101 hasConceptScore W92937101C148125776 @default.
• W92937101 hasConceptScore W92937101C203014093 @default.
• W92937101 hasConceptScore W92937101C2776090121 @default.
• W92937101 hasConceptScore W92937101C2778849806 @default.
• W92937101 hasConceptScore W92937101C2911091166 @default.
• W92937101 hasConceptScore W92937101C3019230761 @default.
• W92937101 hasConceptScore W92937101C71924100 @default.
• W92937101 hasConceptScore W92937101C86803240 @default.
• W92937101 hasConceptScore W92937101C8891405 @default.
• W92937101 hasFunder F4320332161 @default.
• W92937101 hasIssue "3" @default.
• W92937101 hasLocation W929371011 @default.

• next